Accelerated Approval — Taking the FDA’s Concerns Seriously-Reference-Cited by-同舟云学术

Accelerated Approval — Taking the FDA’s Concerns Seriously

Published:2022-07-21 Issue:3 Volume:387 Page:199-201
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Sachs Rachel E.¹,Donohue Julie M.¹,Dusetzina Stacie B.¹

Affiliation:

1. From Washington University in St. Louis School of Law, St. Louis (R.E.S.); the Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh (J.M.D.); and the Department of Health Policy, Vanderbilt University School of Medicine, and the Vanderbilt–Ingram Cancer Center — both in Nashville (S.B.D.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMp2204487

Reference1 articles.

1. Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of post-marketing requirements for oncology drug conditional approvals in the United States and China;Heliyon;2024-08

2. Understanding the Regulatory Pathways Used to Develop, Evaluate, Authorize, and Approve New Drugs and Vaccines in the United States;Journal of the Pediatric Infectious Diseases Society;2024-07-12

3. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

4. Pediatric Drugs, Accelerated Approval, and Prospects for Reform;Pediatric Drugs;2023-10-14

5. Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?;The Lancet Oncology;2023-09